News: Alzheimer's Drugs Show Promise

Printed in the AARP Bulletin March 2021

"A new study by drug company Eli Lilly shows that an experimental drug DONANEMAB may significantly slow cognitive decline in people with Alzheimer's disease.The drug works by targeting the hard plaque in the brain made from amyloid, a protein associated with Alzheimer's. DONANEMAB cleared a significant amount of the amyloid from users, Eli Lilly reports. That slowed the symptoms of the disease in those patients. The drugmaker says it will release more information on the drug tests soon. This isn't the only news Alzheimer's researchers are excited about. There are several new drugs close to getting FDA approval, or in development, that promise to really change the playing field for treatment of Alzheimer's disease, says Marwan Sabbagh, MD, director of the Lou Ruvo Center for Brain Health in Las Vegas."

READ THE ENTIRE ARTICLE IN AARP BULLETIN MARCH 2021